文献速递银屑病与炎症性皮肤病

氯倍他索乳膏与钙泊三醇/倍他米松泡沫剂治疗轻中度斑块状银屑病的非侵入性临床与微观评估

Non-invasive clinical and microscopic evaluation of the response to treatment with clobetasol cream vs. calcipotriol/betamethasone dipropionate foam in mild to moderate plaque psoriasis: an investigator-initiated, phase IV, unicentric, open, randomized clinical trial.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-07-06

这项IV期随机对照试验比较了氯倍他索乳膏与钙泊三醇/倍他米松泡沫剂(Cal/BD泡沫剂)治疗轻中度斑块状银屑病的临床与微观特征。共纳入36例成人患者,第4周时Cal/BD泡沫剂组达到TCS≤1的患者比例显著高于氯倍他索组(63.2% vs. 18.8%,P=0.016),且患者满意度更高、表皮厚度减少更明显。

要点

  • Cal/BD泡沫剂在第4周临床清除率显著优于氯倍他索乳膏。
  • Cal/BD泡沫剂患者满意度更高,表皮厚度减少更明显。
  • 基线有表皮增生者,氯倍他索治疗反应较差。

核心结论

  • Cal/BD泡沫剂比氯倍他索更有效,患者满意度更好,且能更显著减少角化过度/棘层肥厚,无论基线是否存在表皮增生。

研究设计与样本

  • 前瞻性、单中心、开放、随机临床试验,纳入36例成人银屑病患者(22例男性),比较氯倍他索乳膏与Cal/BD泡沫剂的临床(TCS)和微观(皮肤镜、RCM、OCT)数据。

主要发现

  • 第4周时,Cal/BD泡沫剂组达到TCS≤1的患者比例显著高于氯倍他索组(63.2% vs. 18.8%,P=0.016)。
  • Cal/BD泡沫剂组治疗满意度更高(P<0.03)。
  • 第4周时Cal/BD泡沫剂组表皮厚度减少更明显(P<0.049)。
  • 第8周时氯倍他索组扩张的水平血管更常见(69.2% vs. 31.2%,P=0.159)。
  • 基线有表皮增生者,氯倍他索治疗反应较差(P=0.029)。

临床怎么用

  • 对于轻中度斑块状银屑病,Cal/BD泡沫剂可作为优于氯倍他索乳膏的治疗选择。
  • 非侵入性微观评估(皮肤镜、RCM、OCT)可辅助评估治疗反应。
  • 基线表皮增生可能提示对氯倍他索反应不佳,可考虑优先选用Cal/BD泡沫剂。

局限性

  • 样本量小。
  • 开放研究设计。
  • 影像采样偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment response for psoriasis is typically evaluated using clinical scores. However, patients can relapse after clinical clearance, suggesting persistent inflammation. Dermoscopy, reflectance confocal microscopy (RCM) and optical coherence tomography (OCT) can non-invasively improve treatment response assessment. OBJECTIVES: To compare the clinical and non-invasive microscopic features in a psoriatic target lesion treated with clobetasol cream or calcipotriol/betamethasone dipropionate foam (Cal/BD foam). METHODS: Prospective, unicentric, open, randomized clinical trial comparing clinical data [total clinical score (TCS)] and microscopic data (dermoscopy, RCM and OCT) in psoriasis patients treated with clobetasol or Cal/BD foam. RESULTS: We included 36 adult patients (22 men). At week 4, more patients treated with Cal/BD foam achieved TCS ≤1 than with clobetasol (63.2% vs. 18.8%, P = 0.016). Treatment satisfaction was higher with Cal/BD foam (P < 0.03). Microscopically, Cal/BD foam induced more reduction in epidermal thickness at week 4 (P < 0.049). Dilated horizontal blood vessels were more common with clobetasol than with Cal/BD foam at week 8 (69.2% vs. 31.2%, P = 0.159). If epidermal hyperplasia was noted at baseline, the response was poorer with clobetasol (P = 0.029). LIMITATIONS: Small sample size, open study, imaging sampling bias. CONCLUSION: Cal/BD foam is more effective than clobetasol, has better patient satisfaction and induces greater reduction in the hyperkeratosis/acanthosis, regardless of baseline epidermal hyperplasia.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Yélamos O, Alejo B, Ertekin SS, et al. Non-invasive clinical and microscopic evaluation of the response to treatment with clobetasol cream vs. calcipotriol/betamethasone dipropionate foam in mild to moderate plaque psoriasis: an investigator-initiated, phase IV, unicentric, open, randomized clinical trial. J Eur Acad Dermatol Venereol. 2020. PMID: 32365242. doi:10.1111/jdv.16559

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。